CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of ...

NMPA accepts Akeso’s supplemental New Drug Application for gumokimab to treat active ankylosing spondylitis: Hong Kong Wednesday, January 21, 2026, 12:00 Hrs [IST] Akeso Inc, a ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of kidney transplant loss with no approved treatmentsU.S. IND previously approve ...

The global biosimilar monoclonal antibody market revenue was around US$ 10.6 billion in 2023 and is estimated to reach US$ 64.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 22.2 ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

Researchers in Switzerland have conducted the first systematic study that demonstrated that even small variations in a person’s genome can disrupt the therapeutic effects of monoclonal antibodies. “We ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it has submitted a Biologics ...

Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing ...

A look at the clinical progress of anti-Aβ monoclonal antibodies and how precision delivery is shaping the next generation of ...

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...

Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the US Food and Drug Administration (FDA) for its self ...

A new computer model could help predict and improve antibody drug formulations. The goal is for patients to be able to ...